Revenue (Tables)

3 Months Ended

Jul. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The table below illustrates net sales by segment and division for the three months ended July 31, 2020 and July 26, 2019:

	Three months ended(1)
(in millions)	July 31, 2020		July 26, 2019
Cardiac Rhythm & Heart Failure	$	1,247	$	1,382
Coronary & Structural Heart	780		941
Aortic, Peripheral, & Venous	405		467
Cardiac & Vascular Group	2,433		2,790
Surgical Innovations	1,080		1,417
Respiratory, Gastrointestinal, & Renal	720		683
Minimally Invasive Therapies Group	1,801		2,100
Cranial & Spinal Technologies	944		1,050
Specialty Therapies	453		563
Neuromodulation	314		398
Restorative Therapies Group	1,712		2,012
Diabetes Group	562		592
Total	$	6,507	$	7,493

(1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

During the first quarter of fiscal year 2021, the Company realigned the divisions within the Restorative Therapies Group to the following: Cranial & Spinal Technologies (includes Core Spine and Biologics, Enabling Technologies, and China Orthopedics), Specialty Therapies (includes ENT, Pelvic Health, and Neurovascular), and Neuromodulation (includes Pain Therapies, Brain Modulation, and Interventional). As a result, net sales for fiscal year 2020 have been recast to adjust for this realignment.

The table below illustrates net sales by market geography for each segment for the three months ended July 31, 2020 and July 26, 2019:

	U.S.(1)(4)				Non-U.S. Developed Markets(2)(4)				Emerging Markets(3)(4)
	Three months ended				Three months ended				Three months ended
(in millions)	July 31, 2020		July 26, 2019		July 31, 2020		July 26, 2019		July 31, 2020		July 26, 2019
Cardiac & Vascular Group	$	1,206	$	1,361	$	853	$	930	$	374	$	499
Minimally Invasive Therapies Group	722		913		719		791		359		396
Restorative Therapies Group	1,136		1,338		376		426		199		248
Diabetes Group	287		306		226		231		48		55
Total	$	3,351	$	3,918	$	2,175	$	2,377	$	981	$	1,198

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

(4)Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.